PT3814341T - Inibidores de recetor erbb - Google Patents
Inibidores de recetor erbbInfo
- Publication number
- PT3814341T PT3814341T PT198005092T PT19800509T PT3814341T PT 3814341 T PT3814341 T PT 3814341T PT 198005092 T PT198005092 T PT 198005092T PT 19800509 T PT19800509 T PT 19800509T PT 3814341 T PT3814341 T PT 3814341T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor inhibitors
- erbb receptor
- erbb
- inhibitors
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085998 | 2018-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3814341T true PT3814341T (pt) | 2024-04-11 |
Family
ID=68467752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT198005092T PT3814341T (pt) | 2018-05-08 | 2019-05-08 | Inibidores de recetor erbb |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10822334B2 (enExample) |
| EP (2) | EP3814341B1 (enExample) |
| JP (2) | JP7540953B2 (enExample) |
| KR (1) | KR102806778B1 (enExample) |
| CN (4) | CN111587248A (enExample) |
| AR (1) | AR117424A1 (enExample) |
| AU (1) | AU2019267959B2 (enExample) |
| CA (1) | CA3099315A1 (enExample) |
| DK (1) | DK3814341T3 (enExample) |
| ES (1) | ES2977196T3 (enExample) |
| MX (2) | MX2020011868A (enExample) |
| PT (1) | PT3814341T (enExample) |
| TW (2) | TWI811358B (enExample) |
| WO (1) | WO2019214634A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| HRP20240293T1 (hr) | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| TWI879751B (zh) * | 2020-03-23 | 2025-04-11 | 印度商皮埃企業有限公司 | 3-被取代的苯基脒化合物及其製備和用途 |
| KR20230167009A (ko) * | 2020-10-05 | 2023-12-07 | 다나-파버 캔서 인스티튜트 인크. | Her2에 대한 강력하고 선택적인 억제제 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CR20240163A (es) * | 2021-10-20 | 2024-06-12 | Hoffmann La Roche | Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas |
| CN114262327B (zh) * | 2021-12-30 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
| CN114671867B (zh) * | 2022-03-15 | 2023-09-19 | 上海法默生物科技有限公司 | 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法 |
| US20250206760A1 (en) * | 2022-03-28 | 2025-06-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof |
| JPWO2024043252A1 (enExample) | 2022-08-24 | 2024-02-29 | ||
| AU2023410324A1 (en) | 2022-12-22 | 2025-05-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| CN116102491A (zh) * | 2023-02-17 | 2023-05-12 | 浙江晖石药业有限公司 | 一种利用连续流技术进行金属催化偶联的应用 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121568696A (zh) | 2023-07-28 | 2026-02-24 | 勃林格殷格翰国际有限公司 | 制备her2抑制剂的方法 |
| CN119320383A (zh) * | 2023-09-05 | 2025-01-17 | 北京鞍石生物科技股份有限公司 | 含氮杂芳基化合物及其制备方法和应用 |
| CN117534669A (zh) * | 2023-11-01 | 2024-02-09 | 上海凌凯医药科技有限公司 | 五元氮杂环并吡啶醇的制备方法 |
| CN117658818B (zh) * | 2023-11-03 | 2025-02-07 | 江西巍华化学有限公司 | 一种4-氟-3-硝基三氟甲苯的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| RU2004116911A (ru) * | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| ES2354457T3 (es) * | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer. |
| CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物 |
| DE602006021645D1 (de) * | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
-
2019
- 2019-05-07 TW TW108115721A patent/TWI811358B/zh active
- 2019-05-07 AR ARP190101206A patent/AR117424A1/es unknown
- 2019-05-07 TW TW112129260A patent/TWI858848B/zh active
- 2019-05-08 ES ES19800509T patent/ES2977196T3/es active Active
- 2019-05-08 CN CN201980006431.XA patent/CN111587248A/zh active Pending
- 2019-05-08 MX MX2020011868A patent/MX2020011868A/es unknown
- 2019-05-08 AU AU2019267959A patent/AU2019267959B2/en active Active
- 2019-05-08 CN CN202010656946.9A patent/CN111747953B/zh active Active
- 2019-05-08 EP EP19800509.2A patent/EP3814341B1/en active Active
- 2019-05-08 KR KR1020207034917A patent/KR102806778B1/ko active Active
- 2019-05-08 DK DK19800509.2T patent/DK3814341T3/da active
- 2019-05-08 CN CN202010657663.6A patent/CN112266384B/zh active Active
- 2019-05-08 EP EP24164213.1A patent/EP4410291A3/en active Pending
- 2019-05-08 WO PCT/CN2019/085949 patent/WO2019214634A1/en not_active Ceased
- 2019-05-08 JP JP2020562751A patent/JP7540953B2/ja active Active
- 2019-05-08 CN CN202010657654.7A patent/CN111662289A/zh active Pending
- 2019-05-08 PT PT198005092T patent/PT3814341T/pt unknown
- 2019-05-08 CA CA3099315A patent/CA3099315A1/en active Pending
-
2020
- 2020-06-24 US US16/910,267 patent/US10822334B2/en active Active
- 2020-09-23 US US17/029,074 patent/US11447492B2/en active Active
- 2020-11-06 MX MX2023008954A patent/MX2023008954A/es unknown
-
2024
- 2024-01-22 JP JP2024007265A patent/JP7810734B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3814341A4 (en) | HERITAGE RECEPTOR INHIBITORS | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| PT3746424T (pt) | Inibidores de erbb/btk | |
| GB201911187D0 (en) | Receptor | |
| GB201905552D0 (en) | Antagonists | |
| PL3759096T3 (pl) | Inhibitory cd73 | |
| HUE060181T2 (hu) | Szubsztituált alkoxipiridinil-indolszulfonamidok | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| GB201702617D0 (en) | Receptor | |
| IL292104A (en) | egfr inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| GB201815629D0 (en) | Antagonists | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| ZA202003808B (en) | Erbb/btk inhibitors | |
| GB201910526D0 (en) | Antagonist | |
| GB201909500D0 (en) | Antagonist | |
| IL269414A (en) | Rapar for safetyin taneis | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201910865D0 (en) | Antagonist compounds | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201820687D0 (en) | Antagonists | |
| GB201812604D0 (en) | Antagonist compounds | |
| GB201904158D0 (en) | Antagonist compounds |